Blog
What Is Tirzepatide? A Research-Backed Guide to the First Dual GIP/GLP-1 Agonist
What Is Tirzepatide? A Research-Backed Guide to the First Dual GIP/GLP-1 Agonist
Choice Peptide Labs | 14 min read | SURPASS 1-5 clinical trials | June 2026
Tirzepatide is a single molecule that activates two incretin hormone receptors simultaneously — GIP and GLP-1. It’s the first compound of its kind in large-scale clinical trials, with the SURPASS program generating data across thousands of participants.
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor co-agonist — one molecule that activates two different hormone receptors at the same time. Both GIP and GLP-1 are incretin hormones your body releases after eating, playing roles in blood sugar regulation, insulin secretion, and appetite signaling.
Source: Frías, J.P., et al. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” NEJM, 385(6), 503–515. NEJM
The Dual-Receptor Mechanism: GIP + GLP-1
GLP-1 Receptor
- Location: Pancreatic beta cells and brain regions regulating appetite
- Function: Stimulates insulin secretion, suppresses glucagon, signals satiety
- Context: GLP-1 receptor agonists (like semaglutide) have been extensively studied
GIP Receptor
- Location: Pancreatic beta cells, adipose tissue, and brain
- Function: Stimulates insulin, may enhance fat metabolism, independent appetite effects
- Context: GIP agonism was historically considered less important — tirzepatide challenged that
GIP and GLP-1 receptors are co-located in brain regions that regulate food intake. Activating both simultaneously produces additive effects on appetite suppression.
The SURPASS Clinical Trial Program
SURPASS-1 — Monotherapy. Potent glucose-lowering with robust weight loss. (Lancet, 2021)
SURPASS-2 — Head-to-head vs semaglutide 1mg. 1,879 participants. All three tirzepatide doses (5mg, 10mg, 15mg) produced greater HbA1c reductions: 2.1-2.5% vs 1.9%. (NEJM, 2021)
SURPASS-3 — vs insulin degludec. Superior HbA1c reduction and weight loss. (Nature Medicine, 2021)
SURPASS-4 — High cardiovascular risk population. Sustained benefits. (Lancet, 2022)
SURPASS-5 — Add-on to existing insulin. Significant additional HbA1c reduction and weight loss. (JCEM, 2022)
What the Combined Data Shows
| Metric | Tirzepatide | Context |
|---|---|---|
| HbA1c reduction | 2.1% – 2.5% | Superior to semaglutide 1mg (1.9%) |
| Composite endpoint | 43-62% of participants | HbA1c ≤6.5% + ≥10% weight loss, no hypoglycemia |
| 3-year data | Sustained results | Lower progression from prediabetes to Type 2 diabetes |
Source: “Tirzepatide for Obesity Treatment and Diabetes Prevention.” NEJM, 2024. NEJM
Tirzepatide vs. Semaglutide: What’s Different?
| Feature | Tirzepatide | Semaglutide |
|---|---|---|
| Receptor targets | GIP + GLP-1 (dual) | GLP-1 only |
| HbA1c (SURPASS-2) | 2.1% – 2.5% | 1.9% |
| Clinical program | SURPASS 1-5 | STEP 1-5+ |
| Mechanism | Dual receptor agonism | Single receptor agonism |
The 3-Year Follow-Up Data
A 2024 NEJM study followed persons with obesity and prediabetes for 3 years:
- Substantial and sustained weight reduction throughout treatment
- Markedly lower risk of progression from prediabetes to Type 2 diabetes
- Effects did not diminish over the treatment period
How Tirzepatide Works in Plain English
- You eat a meal — your body releases GIP and GLP-1 hormones
- These hormones signal your brain — “you’ve had enough”
- Tirzepatide amplifies both signals — stronger appetite signaling than either alone
- Your pancreas responds — insulin secretion enhanced in a glucose-dependent manner
- Gastric emptying slows — food moves through your stomach more slowly
- Caloric intake decreases — leading to reduced food intake
Frequently Asked Questions
What does tirzepatide do differently from semaglutide?
It activates both GIP and GLP-1 receptors. In SURPASS-2, all three doses produced greater HbA1c reductions than semaglutide 1mg.
What is the SURPASS program?
A five-trial Phase 3 program testing tirzepatide across different populations — monotherapy, vs semaglutide, vs insulin, in cardiovascular risk, and as insulin add-on.
What is GIP?
Glucose-dependent insulinotropic polypeptide — a naturally occurring incretin hormone. GIP receptors are in the pancreas, fat tissue, and brain.
Has tirzepatide been studied long-term?
Yes. A 3-year NEJM study (2024) showed sustained weight reduction and lower diabetes progression risk.
How does tirzepatide affect appetite?
Through central nervous system pathways. GIP and GLP-1 receptors are co-located in brain regions regulating food intake. Dual activation produces stronger satiety signaling.
Is tirzepatide FDA-approved?
Yes. FDA approved in May 2022 for Type 2 diabetes (Mounjaro). Subsequent approvals for obesity treatment followed.
What is a Certificate of Analysis?
An independent lab report showing HPLC purity and mass spectrometry for a specific batch. Choice Peptide Labs publishes one for every batch.
Explore Tirzepatide from Choice Peptide Labs
10mg vial · Published COA · USA-stocked · Cold-chain shipped
Disclaimer: For educational purposes only. Research-grade compounds from Choice Peptide Labs are for laboratory research use only.
